Abiopharma

(10% Negative) Aquestive Therapeutics, Inc. (AQST) Announces Delay in assist Trials for management transition WARREN Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(10% Negative) Keros Therapeutics, Inc. (KROS) Announces Delay in included Trials for Fulton index Due to Pandemic-Related Challenges, Manufacturing Considerations

(99% Neutral) Pacific Biosciences of California, Inc. (PACB) Announces New Board Appointment

(90% Positive) Sanofi (SNY) Announces Clinical Development Update (Form 6-K)

(99% Neutral) Genmab (GMAB) Announces Clinical Development Update (Form 6-K)

(99% Neutral) TALARIS THERAPEUTICS, INC. (TALS) Announces Clinical Development Update

(35% Negative) Mereo BioPharma (MREO) Announces 2021 Annual General Meeting

(99% Neutral) Mereo BioPharma (MREO) Announces Clinical Development Update (Form 6-K)

(10% Negative) Ultragenyx Pharmaceutical Inc. (RARE) Announces Delay in treatments Development Timeline Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(100% Positive) Royalty Pharma plc (RPRX) Provides Update on opportunity for royalty funding in life sciences